- Home
- SPRO vs EBMT Comparison
SPRO vs EBMT Comparison
Compare SPRO & EBMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- EBMT
- Stock Information
- Founded
- SPRO 2013
- EBMT 1922
- Country
- SPRO United States
- EBMT United States
- Employees
- SPRO N/A
- EBMT N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- EBMT Major Banks
- Sector
- SPRO Health Care
- EBMT Finance
- Exchange
- SPRO Nasdaq
- EBMT Nasdaq
- Market Cap
- SPRO 128.9M
- EBMT 134.3M
- IPO Year
- SPRO 2017
- EBMT N/A
- Fundamental
- Price
- SPRO $2.33
- EBMT $16.04
- Analyst Decision
- SPRO Buy
- EBMT
- Analyst Count
- SPRO 4
- EBMT 0
- Target Price
- SPRO $5.00
- EBMT N/A
- AVG Volume (30 Days)
- SPRO 1.2M
- EBMT 18.6K
- Earning Date
- SPRO 11-13-2025
- EBMT 10-28-2025
- Dividend Yield
- SPRO N/A
- EBMT 3.53%
- EPS Growth
- SPRO N/A
- EBMT 58.15
- EPS
- SPRO N/A
- EBMT 1.72
- Revenue
- SPRO $48,576,000.00
- EBMT $87,531,000.00
- Revenue This Year
- SPRO N/A
- EBMT N/A
- Revenue Next Year
- SPRO N/A
- EBMT $5.45
- P/E Ratio
- SPRO N/A
- EBMT $9.33
- Revenue Growth
- SPRO N/A
- EBMT 9.36
- 52 Week Low
- SPRO $0.51
- EBMT $14.35
- 52 Week High
- SPRO $3.22
- EBMT $18.49
- Technical
- Relative Strength Index (RSI)
- SPRO 56.08
- EBMT 32.55
- Support Level
- SPRO $2.16
- EBMT $16.71
- Resistance Level
- SPRO $2.42
- EBMT $17.00
- Average True Range (ATR)
- SPRO 0.12
- EBMT 0.32
- MACD
- SPRO -0.00
- EBMT -0.07
- Stochastic Oscillator
- SPRO 46.85
- EBMT 9.62
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About EBMT Eagle Bancorp Montana Inc.
Eagle Bancorp Montana Inc operates as a bank holding company. It provides loan and deposit services. The company focuses on residential loans, commercial real estate loans, commercial loans, consumer loans, and home equity loan products. The bank also offers deposit accounts which include checking, savings, money market, individual retirement accounts, and certificates of deposit accounts. It is a diversified lender with a focus on residential mortgage loans, commercial real estate mortgage loans, commercial business loans, agricultural loans, and second mortgage/home equity loan products.